Uncategorized
Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol® for the Treatment of Moderate to Severe Dry Eye Disease
HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH announced the completion of enrollment in its Phase 2 clinical trial evaluating the safety, efficacy and tolerability of CyclASol® for the treatment of moderate to severe dry eye disease.
